HSP90 and the chaperoning of cancer
The DOI matches its Crossref record; 148 of the 149 references it cites were found in a registry or an index.
Abstract
Standing watch over the proteome, molecular chaperones are an ancient and evolutionarily conserved class of proteins that guide the normal folding, intracellular disposition and proteolytic turnover of many of the key regulators of cell growth, differentiation and survival. This essential guardian function is subverted during oncogenesis to allow malignant transformation and to facilitate rapid somatic evolution. Pharmacologically 'bribing' the essential guard duty of the chaperone HSP90 (heat-shock protein of 90 kDa) seems to offer a unique anticancer strategy of considerable promise.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HSP90AB1 is commonly overexpressed in a variety of cancers, with this upregulation typically linked to poor prognostic outcomes and increased resistance to standard chemotherapy and radiotherapy treatments [12, 42, 43].”
From Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer (2024) · cites this paper as [43]
In the citing paper
“This role as a potentiator for genetic variation has been observed in fungi as well as mammalian cancer cells20,88,135,136.”
From Fungal Hsp90: a biological transistor that tunes cellular outputs to thermal inputs (2012) · cites this paper as [88]
In the citing paper
“Second, Hsp90 can enable the phenotypic effects of new mutations either by stabilizing mutant regulators or by stabilizing non-mutant regulators that mediate signalling required for adaptation.”
From Fungal Hsp90: a biological transistor that tunes cellular outputs to thermal inputs (2012) · cites this paper as [88]
Citations
Cites
Hsp90 as a capacitor for morphological evolution
Rutherford, S. L., & Lindquist, S. (1998) · Nature · doi:10.1038/24550 · Cited by 2,270 · cited 1×
“melanogaster and Arabidopsis thaliana model systems that HSP90 can conceal inherent genetic variation within populations of organism”
BackgroundSelf-citationWhitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., & Neckers, L. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8324 · Cited by 1,444
Self-citationA high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
Kamal, A., Thao, L., Sensintaffar, J., Zhang, L., Boehm, M. F., Fritz, L. C., & Burrows, F. J. (2003) · Nature · doi:10.1038/nature01913 · Cited by 1,387 · cited 1×
“By contrast, in normal cells, there is a substantial pool of free HSP90 dimers that have low ATPase activity and low drug affinit”
BackgroundHsp90 as a capacitor of phenotypic variation
Queitsch, C., Sangster, T. A., & Lindquist, S. (2002) · Nature · doi:10.1038/nature749 · Cited by 1,372
Self-citationStebbins, C. E., Russo, A. A., Schneider, C., Rosen, N., Hartl, F. U., & Pavletich, N. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80203-2 · Cited by 1,364
Prodromou, C., Roe, S. M., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1997) · Cell · doi:10.1016/s0092-8674(00)80314-1 · Cited by 1,265
Structure of TPR Domain–Peptide Complexes
Scheufler, C., Brinker, A., Bourenkov, G., Pegoraro, S., Moroder, L., Bartunik, H., Hartl, F. U., & Moarefi, I. (2000) · Cell · doi:10.1016/s0092-8674(00)80830-2 · Cited by 1,188
Role of the Heat Shock Response and Molecular Chaperones in Oncogenesis and Cell Death
Jolly, C. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.19.1564 · Cited by 1,048 · cited 1×
“Several detailed reviews are available that address the molecular and cellular biology of the heat-shock respons”
BackgroundThe 90-kDa Molecular Chaperone Family
Csermely, P., Schnaider, T., So″ti, C., Prohászka, Z., & Nardai, G. (1998) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00013-8 · Cited by 1,028
Roe, S. M., Prodromou, C., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980403y · Cited by 1,004 · cited 1×
“Drug binding at the N-terminus of HSP90 has now been shown to alter many of its normal function”
Background
Research works printed but not linked: 2
- McCollum, A., Toft, D. O. & Erlichman, C. Geldanamycin enhances cisplatin cytotoxicity through loss of Akt activation in A549 cells. Clin. Cancer Res. 9 (Suppl.), 6178 (2003).
- Barbosa, J. A. et al. Discovery of novel small molecule Hsp90 complex inhibitors using a forward chemical genetics approach. Clin. Cancer Res. 9 (Suppl.), 6176 (2003).
Cited by
Items 301–400 of 1,008
Hietpas, R. T., Bank, C., Jensen, J. D., & Bolon, D. N. A. (2013) · Evolution · doi:10.1111/evo.12207 · Cited by 114
“…gene (Hsp90, an essential chaperone in eukaryotes [Borkovich et al. 1989] required for the maturation of many kinases [Whitesell et al. 1994; Whitesell and Lindquist 2005]), results were quite clear—with a strong bimodal distribution containing mutations nearly equivalent to wild type,…”
BackgroundQuality control and fate determination of Hsp90 client proteins
Theodoraki, M. A., & Caplan, A. J. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.08.006 · Cited by 127
Metchat, A., Åkerfelt, M., Bierkamp, C., Delsinne, V., Sistonen, L., Alexandre, H., & Christians, E. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808819200 · Cited by 114
Zhang, L., Fan, J., Vu, K., Hong, K., Brazidec, J. L., Shi, J., Biamonte, M. A., Busch, D. J., Lough, R. E., Grecko, R., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051146h · Cited by 116
Estrogen Receptor-α Hinge-Region Lysines 302 and 303 Regulate Receptor Degradation by the Proteasome
Berry, N. B., Fan, M., & Nephew, K. P. (2008) · Molecular Endocrinology · doi:10.1210/me.2007-0449 · Cited by 135
Schulz‐Heddergott, R., Marchenko, N. D., Holembowski, L., Fingerle‐Rowson, G., Pesic, M. H., Zender, L., Dobbelstein, M., & Moll, U. M. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20111117 · Cited by 130
“Given the plethora of known HSP90 clients in tumors (Whitesell and Lindquist, 2005; Taipale et al., 2010; Trepel et al., 2010), it is surprising that MIF turns out to be so im portant for 17AAGmediated inhibition of tumor growth.”
BackgroundInfluentialRichardson, P. G. G., Chanan-Khan, A. A., Lonial, S., Krishnan, A. Y., Carroll, M. P., Alsina, M., Albitar, M. X., Berman, D., MESSINA, M. E., & Anderson, K. C. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08664.x · Cited by 118
“…antibiotic geldanamycin, is an inhibitor of heat shock protein 90 (HSP90), a molecular chaperone that works in a complex with other co-chaperones to facilitate the proper folding and stability of numerous client proteins involved in tumour growth and survival (Whitesell & Lindquist, 2005).”
BackgroundSharma, K., Vabulas, R. M., Macek, B., Pinkert, S., Cox, J., Mann, M., & Hartl, F. U. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.014654 · Cited by 114
“Although EGFR is a client protein that is degraded in response to Hsp90 inhibition, Hsp27 is one of the heat shock proteins that are induced by HSF1 after this transcription factor is released from an inhibitory association with Hsp90 by 17-DMAG (17).”
BackgroundGould, C. M., Kannan, N., Taylor, S. S., & Newton, A. C. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808436200 · Cited by 113
Hsp90: A New Player in DNA Repair?
Pennisi, R., Ascenzi, P., & Di Masi, A. (2015) · Biomolecules · doi:10.3390/biom5042589 · Cited by 112
“The increased expression of one or more chaperones above the level observed in normal tissues is a common feature of both solid tumors and hematological malignancies [30,33,42].”
BackgroundDevelopment of a Grp94 inhibitor
Duerfeldt, A. S., Peterson, L. B., Maynard, J. C., Ng, C. L., Eletto, D., Ostrovsky, O., Shinogle, H. E., Moore, D. S., Argon, Y., Nicchitta, C. V., et al. (2012) · Journal of the American Chemical Society · doi:10.1021/ja303477g · Cited by 113
Ganetespib and HSP90: Translating Preclinical Hypotheses into Clinical Promise
Proia, D. A., & Bates, R. C. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3263 · Cited by 110
Parthenolide as Cooperating Agent for Anti-Cancer Treatment of Various Malignancies
Sztiller-Sikorska, M., & Czyż, M. (2020) · Pharmaceuticals · doi:10.3390/ph13080194 · Cited by 113
“Heat-shock proteins (HSP) are often overexpressed in human solid tumors and hematological malignancies [163].”
BackgroundHSP90 regulates DNA repair via the interaction between XRCC1 and DNA polymerase β
Fang, Q., Inanc, B., Schamus, S., Wang, X.-H., Wei, L., Brown, A. R., Svilar, D., Sugrue, K. F., Goellner, E. M., Zeng, X., et al. (2014) · Nature Communications · doi:10.1038/ncomms6513 · Cited by 110
“In many cases, heat shock chaperone (HSP90) client proteins are protected from ubiquitylation 40 .”
Lin, T.-Y., Bear, M., Du, Z., Foley, K. P., Ying, W., Barsoum, J., & London, C. (2008) · Experimental Hematology · doi:10.1016/j.exphem.2008.05.001 · Cited by 111
“Adequate HSP90 function is required by tumor cells to maintain appropriate client protein expression necessary for proliferation and survival [27,28].”
Heat Shock Proteins and HSF1 in Cancer
Cyran, A. M., & Zhitkovich, A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.860320 · Cited by 117
“2 HSP90 in Cancer HSP90 has long been recognized as an attractive therapeutic target due to its frequent overexpression in various cancers and its importance in the maintenance of a proper conformation for components of various oncogenic pathways (17, 22).”
BackgroundProtein aggregation as a paradigm of aging
Lindner, A. B., & Démarez, A. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2009.06.005 · Cited by 127
Sakatani, M., Alvarez, N. V., Takahashi, M., & Hansen, P. J. (2012) · Journal of Dairy Science · doi:10.3168/jds.2011-4986 · Cited by 111
Roué, G., Pérez‐Galán, P., Mozos, A., López‐Guerra, M., Xargay‐Torrent, S., Rosich, L., Saborit-Villarroya, I., Normant, E., Campo, E., & Colomer, D. (2010) · Blood · doi:10.1182/blood-2010-04-278853 · Cited by 116
Natural Product Inspired N‐Terminal Hsp90 Inhibitors: From Bench to Bedside?
Khandelwal, A., Crowley, V. M., & Blagg, B. S. J. (2015) · Medicinal Research Reviews · doi:10.1002/med.21351 · Cited by 121
Raf kinases: Oncogenesis and drug discovery
Schreck, R., & Rapp, U. R. (2006) · International Journal of Cancer · doi:10.1002/ijc.22144 · Cited by 124
Prostate cancer relevant antigens and enzymes for targeted drug delivery
Barve, A. J., Jin, W., & Cheng, K. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.035 · Cited by 115
Shi, Y., Liu, X., Lou, J., Han, X., Zhang, L., Wang, Q., Li, B., Dong, M., & Zhang, Y. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0174 · Cited by 111
“Such proteins maintain active protein conformation and intracellular disposition for growth and survival of cells (6, 7).”
BackgroundProteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer
McGrail, D. J., Garnett, J., Yin, J., Dai, H., Shih, D. J. H., Lam, T., Li, Y., Sun, C., Li, Y., Schmandt, R. E., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.01.011 · Cited by 120
“Protein folding chaperones can contribute to tumor survival by helping to stabilize the proteome regardless of mutational burden, leading to the development of specific heat shock protein inhibitors with therapeutic potential (Whitesell and Lindquist, 2005).”
BackgroundThe heat shock response and small molecule regulators
Kurop, M. K., Huyen, C. M., Kelly, J. H., & Blagg, B. S. J. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113846 · Cited by 112
Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target
Schulz-Heddergott, R., & Moll, U. (2018) · Cancers · doi:10.3390/cancers10060188 · Cited by 105
Wei, H., Zhang, R., Su, Y., Bi, Y., Li, X., Zhang, X., Li, J., & Bao, J. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01589 · Cited by 114
Fungal Hsp90: a biological transistor that tunes cellular outputs to thermal inputs
Leach, M. D., Klipp, E., Cowen, L. E., & Brown, A. J. P. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2875 · Cited by 107
Condelli, V., Crispo, F., Pietrafesa, M., Lettini, G., Matassa, D. S., Esposito, F., Landriscina, M., & Maddalena, F. (2019) · Cells · doi:10.3390/cells8060532 · Cited by 104
“In such a context, several authors described HSP90 upregulation in human malignancies as a key event in carcinogenesis and tumor progression [66].”
BackgroundAcquaviva, J., Smith, D. L., Jimenez, J.-P., Zhang, C., Sequeira, M., He, S., Sang, J., Bates, R. C., & Proia, D. A. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0481 · Cited by 101
“facilitating aberrant cell survival and oncogene addiction (11, 12).”
BackgroundRegulation of activation-induced deaminase stability and antibody gene diversification by Hsp90
Orthwein, A., Patenaude, A., Affar, E. B., Lamarre, A., Young, J. C., & Noia, J. M. D. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20101321 · Cited by 119
“We speculate that AID, just as the steroid hormone receptors (Whitesell and Lindquist, 2005; Picard, 2006), might undergo some conformational change to dissociate from Hsp90.”
InfluentialFan, A. C. Y., Bhangoo, M. K., & Young, J. C. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605250200 · Cited by 103
Kuruma, H., Matsumoto, H., Shiota, M., Bishop, J. L., Lamoureux, F., Thomas, C., Briere, D. M., Los, G., Gleave, M. E., Fanjul, A. N., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0798 · Cited by 114
“, abiraterone) (13, 20, 27), as well as AR chaperone inhibitors (28-31).”
BackgroundIt’s not magic – Hsp90 and its effects on genetic and epigenetic variation
Zabinsky, R. A., Mason, G. A., Queitsch, C., & Jarosz, D. F. (2018) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2018.05.015 · Cited by 118
The Chemical Biology of Molecular Chaperones—Implications for Modulation of Proteostasis
Brandvold, K. R., & Morimoto, R. I. (2015) · Journal of Molecular Biology · doi:10.1016/j.jmb.2015.05.010 · Cited by 121
“of HSP90 supports oncogenic transformation [33], which is largely attributed to its role in the stabilization of signaling proteins involved in cell growth and proliferation [34], evasion of apoptosis [35], and metastasis [36].”
Schrage, Y. M., Lam, S., Jochemsen, A. G., Cleton-Jansen, A., Taminiau, A. H. M., Hogendoorn, P. C. W., & Bovée, J. V. M. G. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00406.x · Cited by 105
“, 2005 [38]).”
Regulation of protein turnover by heat shock proteins
Bozaykut, P., Özer, N. K., & Karademir-Yilmaz, B. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.08.012 · Cited by 128
Mandal, A. K., Lee, P., Chen, J. A., Nillegoda, N., Heller, A., DiStasio, S., Oen, H., Victor, J., Nair, D. M., Brodsky, J. L., et al. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200604106 · Cited by 104
“Both chaperones interact directly with kinases during folding, and inhibition of Hsp90 with geldanamycin or other ansamycin antibiotics results in the rapid proteasome-dependent degradation of client kinases and transcription factors (MacLean and Picard, 2003; Pearl, 2005; Whitesell and Lindquist, 2005).”
HSP90 inhibition: two-pronged exploitation of cancer dependencies
Travers, J., Sharp, S. Y., & Workman, P. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.12.021 · Cited by 110
Inhibition of heat-shock protein 90 reduces Ebola virus replication
Smith, D. R., McCarthy, S., Chrovian, A., Olinger, G., Stossel, A., Geisbert, T. W., Hensley, L. E., & Connor, J. H. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2010.04.015 · Cited by 104
“Because of this, several Hsp90 inhibitors are now in phase I and II clinical trials (Goetz et al., 2005; Whitesell and Lindquist, 2005).”
BackgroundProtein–Protein Interactions in the Molecular Chaperone Network
Freilich, R., Arhar, T., Abrams, J. L., & Gestwicki, J. E. (2018) · Accounts of Chemical Research · doi:10.1021/acs.accounts.8b00036 · Cited by 105
Sunkara, V., Kim, C., Park, J., Woo, H., Kim, D., Ha, H. K., Kim, M., Son, Y., Kim, J.-R., & Cho, Y. (2019) · Theranostics · doi:10.7150/thno.32438 · Cited by 109
“HSP90, which is a member of heat-shock proteins, is known for its chaperoning activity to protect a number of proteins involved in cancer progression, thereby promoting cancer-cell survival [41-43].”
BackgroundHistone Deacetylase Inhibitors in the Treatment of Hematological Malignancies and Solid Tumors
Federico, M., & Bagella, L. (2011) · BioMed Research International · doi:10.1155/2011/475641 · Cited by 98
“Here, we will discuss some of the recent developments in clinical trials utilizing HDACs inhibitors for the treatment of both hematological malignancies as well as solid tumors.”
Kang, B. H., Siegelin, M. D., Plescia, J., Raskett, C. M., Garlick, D. S., Dohi, T., Lian, J. B., Stein, G. S., Languino, L. R., & Altieri, D. C. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1818 · Cited by 104
The Stress-Like Cancer Cell State Is a Consistent Component of Tumorigenesis
Baron, M., Tagore, M., Hunter, M. V., Kim, I. S., Moncada, R., Yan, Y., Campbell, N. R., White, R. M., & Yanai, I. (2020) · Cell Systems · doi:10.1016/j.cels.2020.08.018 · Cited by 106
Schulz‐Heddergott, R., Streller, F., Scheel, A. H., Rüschoff, J. H., Reinert, M.-C., Dobbelstein, M., Marchenko, N. D., & Moll, U. M. (2014) · Cell Death and Disease · doi:10.1038/cddis.2013.508 · Cited by 109
“Thus, cancer cells become addicted to the HSP machinery, which is highly upregulated and activated specifically in cancer but not in normal cells, turns it in a powerful prosurvival and anti-apoptotic system.(34) Mechanistically, cancer cells respond to their proteotoxic stress by constitutive activation of heat-shock…”
BackgroundChang, D.-J., An, H., Kim, K.-S., Kim, H. H., Jung, J., Lee, J. M., Kim, N., Han, Y. T., Yun, H., Lee, S.-J., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301488q · Cited by 112
Fiskus, W. C., Pranpat, M., Balasis, M. E., Bali, P., Estrella, V. C., Kumaraswamy, S., Rao, R., Rocha, K., Herger, B. E., Lee, F. Y., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0980 · Cited by 102
Hamamoto, R., Toyokawa, G., Nakakido, M., Ueda, K., & Nakamura, Y. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.05.014 · Cited by 110
“293T cells were co-transfected with a FLAGSMYD2 expression vector and four different lengths of HA-HSP90AB1 vectors ([1–724], [1–500], [250–724] and [500–724]).”
BackgroundLu, Z., Jin, Y., Qiu, L., Lai, Y., & Pan, J. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.09.006 · Cited by 103
“HSP90 is overexpressed in both solid tumors and hematological malignancies compared with normal tissues [23].”
BackgroundTargeting KRAS-Mutant Non–Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib
Acquaviva, J., Smith, D. L., Sang, J., Friedland, J. C., He, S., Sequeira, M., Zhang, C., Wada, Y., & Proia, D. A. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0615 · Cited by 96
“Of note, cancer cells exploit the Hsp90 chaperone machinery as a biochemical buffer to protect a variety of mutated and/or overexpressed oncoproteins from targeted degradation, thereby facilitating aberrant cell survival and oncogene addiction (18, 19).”
BackgroundOno, K., Sogawa, C. A., Kawai, H., Tran, M. T., Taha, E. A., Lu, Y., Oo, M. W., Okusha, Y., Okamura, H., Ibaragi, S., et al. (2020) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2020.1769373 · Cited by 102
Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy
Song, B., Yang, P., & Zhang, S. (2024) · 癌症:英文版 · doi:10.1002/cac2.12520 · Cited by 107
Molecular Aspects of the Stress Response: Chaperones, Membranes and Networks
Csermely, P., & VÃgh, L. (2007) · Springer eBooks · doi:10.1007/978-0-387-39975-1 · Cited by 104
Manchado, M., Salas-Leitón, E., Infante, C., Ponce, M., Asensio, E., Crespo, A., Zuasti, E., & Cañavate, J. P. (2008) · Gene · doi:10.1016/j.gene.2008.03.007 · Cited by 111
“These “client proteins” include nuclear hormone receptors, protein kinases, transcription factors, and several other essential regulatory proteins (Whitesell and Lindquist, 2005; Brown et al., 2007).”
Anti-Hsp90 therapy in autoimmune and inflammatory diseases: a review of preclinical studies
Tukaj, S., & Węgrzyn, G. (2016) · Cell Stress and Chaperones · doi:10.1007/s12192-016-0670-z · Cited by 104
A covalently bound inhibitor triggers EZH2 degradation through CHIP‐mediated ubiquitination
Wang, X., Cao, W., Zhang, J., Yan, M., Xu, Q., Wu, X., Wan, L., Zhang, Z., Zhang, C., Qin, X., et al. (2017) · The EMBO Journal · doi:10.15252/embj.201694058 · Cited by 102
“…for ubiquitination-mediated degradation by the COOH terminus of Hsp70-interacting protein (CHIP), a key player in the protein quality control system that mediates the polyubiquitination of misfolded or aggregated proteins for degradation (Whitesell & Lindquist, 2005; Ferreira et al , 2013).”
Tailoring of Proteostasis Networks with Heat Shock Factors
Joutsen, J., & Sistonen, L. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a034066 · Cited by 106
“Because of their unstable proteome, abnormally high expression of HSPs has been observed in a wide range of human cancers and is currently considered as a general feature of neoplastic cells (Whitesell and Lindquist 2005).”
BackgroundEmerging Roles of Extracellular Hsp90 in Cancer
Wong, D. S., & Jay, D. G. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.01.001 · Cited by 101
Paul, S., & Mahanta, S. K. (2013) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-013-1844-y · Cited by 111
“Hsp90 Cytoplasm Maturation and activation of number of proteins [29] Mol Cell Biochem (2014) 386:45–61 47”
BackgroundThe ATPase Cycle of the Mitochondrial Hsp90 Analog Trap1
Leskovar, A., Wegele, H., Werbeck, N. D., Buchner, J., & Reinstein, J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709516200 · Cited by 97
Shelton, S. N., Shawgo, M. E., Matthews, S. B., Lu, Y., Donnelly, A. C., Szabla, K., Tanol, M., Vielhauer, G. A., Rajewski, R. A., Matts, R. L., et al. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.058545 · Cited by 99
“A growing number of natural product, synthetic, and semisynthetic Hsp90 inhibitors are being developed that largely target the N-terminal ATP-binding pocket and have been shown to cause potent antiproliferative effects (Roe et al., 1999; Whitesell and Lindquist, 2005; Avila et al., 2006a,b).”
BackgroundInfluentialProtein Kinase CK2 in Health and Disease: CK2: The kinase controlling the Hsp90 chaperone machinery
Miyata, Y. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-9152-0 · Cited by 98
Hyperthermia-induced DNA repair deficiency suggests novel therapeutic anti-cancer strategies
Eppink, B., Krawczyk, P. M., Stap, J., & Kanaar, R. (2012) · International Journal of Hyperthermia · doi:10.3109/02656736.2012.695427 · Cited by 103
“Over 200 Hsp90 client proteins have been identified, including factors relevant for chromatin remodelling, DNA repair, cellular homeostasis, transcriptional regulation, signalling and tumour immunology [64, 66–69].”
BackgroundConnecting the nucleolus to the cell cycle and human disease
Tsai, R. Y. L., & Pederson, T. (2014) · The FASEB Journal · doi:10.1096/fj.14-254680 · Cited by 104
Serwetnyk, M. A., & Blagg, B. S. J. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.11.015 · Cited by 103
Prasad, B. D., Goel, S., & Krishna, P. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012761 · Cited by 109
“Hsp90-specific inhibitors such as geldanamycin (GA) bind to the N-terminal domain of Hsp90 and inhibit its in vivo functions [3].”
BackgroundGallerne, C., Prola, A., & Lemaire, C. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.02.014 · Cited by 102
Zhang, P., Liu, X., Li, M., Ma, Y., Sun, H., Tian, X., Wang, Y., Liu, M., Fu, L.-S., Wang, Y., et al. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113771 · Cited by 99
Kawanami, D., Mahabeleshwar, G. H., Lin, Z., Atkins, G. B., Hamik, A., Haldar, S. M., Maemura, K., LaManna, J. C., & Jain, M. K. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.025346 · Cited by 95
Proteasomal Degradation of Nod2 Protein Mediates Tolerance to Bacterial Cell Wall Components
Lee, K.-H., Biswas, A., Liu, Y.-J., & Kobayashi, K. S. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.410027 · Cited by 93
“Its main functions include the regulation of protein activity, prevention of aggregation of refolded peptides, and maintenance of protein stability (49) To evaluate the effect of Hsp90 dissociation fromNod2, we treated cells with Hsp90 inhibitors, 17AAG and radicicol (RAD), to disrupt the interaction between Hsp90 and…”
MethodKrämer-Marek, G., Kiesewetter, D. O., & Capala, J. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057695 · Cited by 97
“It is required for the stability and function of many client proteins that promote cancer cell growth and survival (4).”
BackgroundMimnaugh, E. G., Xu, W., Vos, M. D., Yuan, X., & Neckers, L. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0019 · Cited by 98
“Both 17-AAG (5, 10) and Velcade (22-25) show promising clinical activity against various human cancers, and these drugs are currently in multiple advanced combinatory trials with standard first-line anticancer drugs (9, 26).”
BackgroundPosttranslational regulation of the NKG2D ligand Mult1 in response to cell stress
Nice, T. J., Coscoy, L., & Raulet, D. H. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20081335 · Cited by 98
“Since the heat shock proteins facilitate an increased metabolic output and also protect against apoptosis, it is not surprising that many of these proteins are also overexpressed in cancer cells (Jolly and Morimoto 2000; Whitesell and Lindquist 2005).”
BackgroundNakashima, T., Ishii, T., Tagaya, H., Seike, T., Nakagawa, H., Kanda, Y., Akinaga, S., Soga, S., & Shiotsu, Y. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3112 · Cited by 102
“Given the critical roles played by Hsp90 and its client proteins in oncogenesis, targeting Hsp90 has emerged as a possible strategy for treatment of advanced cancers, including MM (4, 5).”
BackgroundCloutier, P., & Coulombe, B. (2013) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2013.02.010 · Cited by 108
“Hsp90 has been implicated in a number of cancers, mostly due to the stabilization of overexpressed oncogenic proteins, both mutant and normal [84,85].”
BackgroundSelection Transforms the Landscape of Genetic Variation Interacting with Hsp90
Geiler‐Samerotte, K., Zhu, Y. O., Goulet‐Scott, B. E., Hall, D. W., & Siegal, M. L. (2016) · PLoS Biology · doi:10.1371/journal.pbio.2000465 · Cited by 100
Janssens, G. E., Lin, X.-X., Millan-Ariño, L., Kavšek, A., Sen, I., Seinstra, R. I., Stroustrup, N., Nollen, E. A. A., & Riedel, C. G. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.03.044 · Cited by 94
Martin-Fernandez, M. L., Clarke, D. T., Roberts, S. K., Zanetti-Domingues, L. C., & Gervasio, F. L. (2019) · Cells · doi:10.3390/cells8040316 · Cited by 100
“What is more, the increased expression of Hsp90 allows cancer cells to tolerate adverse environments and internal alterations deriving from accumulated mutations that would otherwise be lethal [28,29].”
BackgroundSong, K., Oh, S. J., Kim, S., Cho, H., Lee, H.-J., Song, J. S., Chung, J., Cho, E., Lee, J., Jeon, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14259-y · Cited by 105
Treatment of Metastatic Uveal Melanoma: Systematic Review
Rodríguez-Vidal, C., Fernández‐Díaz, D., Fernandez-Marta, B., Lago‐Baameiro, N., Pardo, M., Silva, P., Paniagua, L., Blanco‐Teijeiro, M. J., Piñeiro, A., & Bande, M. F. (2020) · Cancers · doi:10.3390/cancers12092557 · Cited by 99
“It interacts with several client proteins, including signaling kinases (RAF and AKT), growth factor receptors (MET and KIT), and cell cycle regulators [120,121].”
BackgroundGarbis, S., Tyritzis, S., Roumeliotis, T., Zerefos, P., Giannopoulou, E. G., Vlahou, A., Kossida, S., Diaz, J. I., Vourekas, S., Tamvakopoulos, C., et al. (2008) · Journal of Proteome Research · doi:10.1021/pr800060r · Cited by 85
The Hsp90 Molecular Chaperone Modulates Multiple Telomerase Activities
Toogun, O. A., DeZwaan, D. C., & Freeman, B. C. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01417-07 · Cited by 93
“Accelerating the interest in Hsp90 is its developing use as a therapeutic target for diverse diseases (27, 42).”
BackgroundGP96 is a GARP chaperone and controls regulatory T cell functions
Zhang, Y., Wu, B. X., Metelli, A., Thaxton, J. E., Hong, F., Rachidi, S., Ansa-Addo, E., Sun, S., Vasu, C., Yang, Y., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79014 · Cited by 95
“Moreover, through its ability to buffer mutations, HSP90 appears to be an important capacitor for morphogenic evolution and oncogenesis (52, 53).”
Protein Homeostasis as a Therapeutic Target for Diseases of Protein Conformation
Calamini, B., & I. Morimoto, R. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026611212220014 · Cited by 91
Dahiya, V., Agam, G., Lawatscheck, J., Rutz, D. A., Lamb, D. C., & Buchner, J. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.03.026 · Cited by 89
Bagatell, R., Gore, L., Egorin, M. J., Ho, R., Heller, G., Boucher, N., Zuhowski, E. G., Whitlock, J. A., Hunger, S. P., Narendran, A., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1892 · Cited by 93
Self-citationExtracellular Hsp90 (eHsp90) as the Actual Target in Clinical Trials
Li, W., Tsen, F., Sahu, D., Bhatia, A., Chen, M., Multhoff, G., & Woodley, D. T. (2013) · International review of cytology · doi:10.1016/b978-0-12-407697-6.00005-2 · Cited by 106
“…the list of its “client” proteins, many of which play a critical role in the survival, migration, proliferation, differentiation and apoptosis of the cells, such as ErbB2, MET, RAF, AKT, BCR-ABL, CDK4, and HIF-1α (Isaacs et al., 2003; Whitesell and Lindquist, 2005; Powers and Workman, 2006).”
BackgroundSystematic Identification of the HSP90 Regulated Proteome
Wu, Z., Moghaddas Gholami, A., & Kuster, B. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.016675 · Cited by 94
“The disruption of HSP90 function by small molecule drugs has therefore become an attractive therapeutic strategy and about a dozen of HSP90 inhibitors are currently undergoing clinical trials in a number of tumor entities and indications (2, 5, 6).”
BackgroundChadli, A., Felts, S. J., Wang, Q., Sullivan, W. P., Botuyan, M. V., Fauq, A., Ramirez-Alvarado, M., & Mer, G. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.081018 · Cited by 94
Stingl, L., Stühmer, T., Chatterjee, M., Jensen, M. R., Flentje, M. P., & Djuzenova, C. S. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605683 · Cited by 94
“Heat-shock proteins 90 (Hsp90s) are ubiquitously and abundantly expressed polypeptides required for the energy-driven stabilisation, conformation and function of a large number of cellular proteins, termed Hsp90 clients (Picard, 2002; Whitesell and Lindquist, 2005).”
BackgroundYano, A., Tsutsumi, S., Soga, S., Lee, M.-J., Trepel, J., Osada, H., & Neckers, L. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805354105 · Cited by 93
Quanz, M., Herbette, A., Sayarath, M., de Koning, L., Dubois, T., Sun, J.-S., & Dutreix, M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.320887 · Cited by 90
“Hsp90 protects some of its clients from degradation via the ubiquitin-proteasome pathway (64).”
BackgroundKoga, F., Kihara, K., & Neckers, L. (2009) · PubMed · Cited by 109
Genetic and Genomic Architecture of the Evolution of Resistance to Antifungal Drug Combinations
Hill, J. A., Ammar, R., Torti, D., Nislow, C., & Cowen, L. E. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003390 · Cited by 93
“This has helped fuel research on Hsp90 as a target for development of anti-cancer drugs, where inhibiting Hsp90 can impair the function of a multitude of oncoproteins [62–64].”
BackgroundSnapShot: Molecular Chaperones, Part I
Chang, H.-C., Tang, Y., Hayer-Hartl, M. K., & Hartl, F. U. (2007) · Cell · doi:10.1016/j.cell.2007.01.001 · Cited by 93
RetractedPhosphoproteomic analysis of Leishmania donovani pro‐ and amastigote stages
Morales, M. A., Watanabe, R., Laurent‐Winter, C., Lenormand, P., Rousselle, J.-C., Namane, A., & Späth, G. F. (2008) · PROTEOMICS · doi:10.1002/pmic.200700697 · Cited by 105
Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors
Rubin, B. P., & Duensing, A. U. (2006) · Laboratory Investigation · doi:10.1038/labinvest.3700466 · Cited by 93
“HSPs are molecular chaperones that guide the normal folding, intracellular disposition and proteolytic turnover of many proteins”
BackgroundMeli, M., Pennati, M., Curto, M., Daidone, M. G., Plescia, J., Toba, S., Altieri, D. C., Zaffaroni, N., & Colombo, G. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060836y · Cited by 93
Hsp90 inhibitors as senolytic drugs to extend healthy aging
Fuhrmann-Stroissnigg, H., Niedernhofer, L. J., & Robbins, P. D. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1475828 · Cited by 92
“In addition to cytosolic HSP90, there are two organelle-specific isoforms, the endoplasmatic reticulum (ER) localized 94-kDa glucose-regulated protein (Grp94) and the mitochondrial tumor necrosis factor (TNF) receptor-associated protein 1 (Trap1) that are both upregulated under cell stress.”
Influential
Metadata
- Authors
- Whitesell, L., & Lindquist, S. L.
- Affiliations
- University of Arizona (US)
- Whitehead Institute for Biomedical Research (US)
- Corresponding author
- Whitesell, Luke
- ORCID
- Whitesell, Luke
- Venue
- Nature Reviews Cancer
- Published
- 2005-09-20
- Volume
- 5
- Issue
- 10
- Pages
- 761-772
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2022531767
- Cited by
- 2,502
- References
- 149
- Citations by year
- 2026: 81 · 2025: 87 · 2024: 83 · 2023: 97 · 2022: 90 · 2021: 113 · 2020: 123 · 2019: 142 · 2018: 99 · 2017: 116 · 2016: 126 · 2015: 152 · 2014: 154 · 2013: 153 · 2012: 167
- FWCI
- 7.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- HSP90, molecular chaperones, carcinogenesis, malignant transformation, somatic evolution, protein folding, proteome, anticancer drug targets, chaperone inhibition
- MeSH terms
- Animals, Humans, Neoplasms, Molecular Chaperones, HSP90 Heat-Shock Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.